Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients

Colapicchioni, Valentina; Tilio, Martina; Digiacomo, Luca; Gambini, Valentina; Palchetti, Sara; Marchini, Cristina; Pozzi, Daniela; Occhipinti, Sergio; Amici, Augusto; Caracciolo, Giulio

doi:10.1016/j.biocel.2015.09.002

Cited by 123 publications

(94 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the first study were confirmed by Colapicchioni et al 26 (Figure 3) in the course of evaluating PPCs formed on clinically approved liposomes (AmBisome) in gastric, breast, and pancreatic cancer patients (10 individuals per disease). The authors found that changes in the liposome’s size attributable to the PC were similar between healthy volunteers and cancer patients.…”

Section: Disease-induced Variability In the Protein Corona Compositionsupporting

confidence: 55%

“…Herein we introduce two recent studies featuring extensive analysis of changes in the PC composition in a wide range of diseases. 20,26 …”

Section: Disease-induced Variability In the Protein Corona Compositionmentioning

confidence: 99%

“…20 Other groups have proven that the plasma proteome is not always consistent, even in healthy individuals, either in terms of composition or abundance of certain proteins. 26 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Personalized protein corona on nanoparticles and its clinical implications

et al. 2017

View full text Add to dashboard Cite

It is now well understood that once in contact with biological fluids, nanoscale objects lose their original identity and acquire a new biological character, referred to as a protein corona. The protein corona changes many of the physicochemical properties of nanoparticles, including size, surface charge, and aggregation state. These changes, in turn, affect the biological fate of nanoparticles, including their pharmacokinetics, biodistribution, and therapeutic efficacy. It is progressively being accepted that even slight variations in the composition of a protein source (e.g., plasma and serum) can substantially change the composition of the corona formed on the surface of the exact same nanoparticles. Recently it has been shown that the protein corona is strongly affected by the patient’s specific disease. Therefore, the same nanomaterial incubated with plasma proteins of patients with different pathologies adsorb protein coronas with different compositions, giving rise to the concept of personalized protein corona. Herein, we review this concept along with recent advances on the topic, with a particular focus on clinical relevance.

show abstract

Section: Disease-induced Variability In the Protein Corona Compositionsupporting

confidence: 55%

“…Herein we introduce two recent studies featuring extensive analysis of changes in the PC composition in a wide range of diseases. 20,26 …”

Section: Disease-induced Variability In the Protein Corona Compositionmentioning

confidence: 99%

See 1 more Smart Citation

Personalized protein corona on nanoparticles and its clinical implications

et al. 2017

View full text Add to dashboard Cite

show abstract

“…20–22, 183 Therefore, this “disease-specific” protein corona adds complications to the actual in vivo intracellular trafficking of NPs and needs more attention in future studies.…”

Section: Intracellular Traffickingmentioning

confidence: 99%

Cellular uptake of nanoparticles: journey inside the cell

et al. 2017

View full text Add to dashboard Cite

Nanoscale materials are increasingly found in consumer goods, electronics, and pharmaceuticals. While these particles interact with the body in myriad ways, their beneficial and/or deleterious effects ultimately arise from interactions at the cellular and subcellular level. Nanoparticles (NPs) can modulate cell fate, induce or prevent mutations, initiate cell-cell communication, and modulate cell structure in a manner dictated largely by phenomena at the nano-bio interface. Recent advances in chemical synthesis have yielded new nanoscale materials with precisely defined biochemical features, and emerging analytical techniques have shed light on nuanced and context-dependent nano-bio interactions within cells. In this review, we provide an objective and comprehensive account of our current understanding of the cellular uptake of NPs and the underlying parameters controlling the nano-cellular interactions, along with the available analytical techniques to follow and track these processes.

show abstract

“…[219] Since many diseases affect both the concentration and the composition of plasma proteins, any drug carrier administered to patients will be exposed to biological environments that vary depending on the disease. [219,220] Furthermore, even patients with the same type of disease can show variations in the concentration and composition of plasma proteins, due to differences in age, gender, medical history etc. [221] Therefore, for drug carriers administered to patients, different biomolecular coronas will form.…”

Section: Perspectives and Conclusionmentioning

confidence: 99%

Particle Targeting in Complex Biological Media

Dai

Bertleff‐Zieschang

Braunger

et al. 2017

Adv Healthcare Materials

102

View full text Add to dashboard Cite

Over the past few decades, nanoengineered particles have gained increasing interest for applications in the biomedical realm, including diagnosis, imaging, and therapy. When functionalized with targeting ligands, these particles have the potential to interact with specific cells and tissues, and accumulate at desired target sites, reducing side effects and improve overall efficacy in applications such as vaccination and drug delivery. However, when targeted particles enter a complex biological environment, the adsorption of biomolecules and the formation of a surface coating (e.g., a protein corona) changes the properties of the carriers and can render their behavior unpredictable. For this reason, it is of importance to consider the potential challenges imposed by the biological environment at the early stages of particle design. This review describes parameters that affect the targeting ability of particulate drug carriers, with an emphasis on the effect of the protein corona. We highlight strategies for exploiting the protein corona to improve the targeting ability of particles. Finally, we provide suggestions for complementing current in vitro assays used for the evaluation of targeting and carrier efficacy with new and emerging techniques (e.g., 3D models and flow‐based technologies) to advance fundamental understanding in bio‐nano science and to accelerate the development of targeted particles for biomedical applications.

show abstract

Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients

Cited by 123 publications

References 42 publications

Personalized protein corona on nanoparticles and its clinical implications

Personalized protein corona on nanoparticles and its clinical implications

Cellular uptake of nanoparticles: journey inside the cell

Particle Targeting in Complex Biological Media

Contact Info

Product

Resources

About